CJC-1295 no DAC / Ipamorelin Blend: A Comprehensive Research Monograph

Overview

The CJC-1295 no DAC / Ipamorelin blend combines two complementary growth hormone-stimulating peptides that act through distinct but synergistic receptor pathways, producing a growth hormone (GH) response that is among the most robust achievable through peptide-based stimulation. This combination represents the practical application of one of the most well-characterized phenomena in neuroendocrine pharmacology: the synergistic interaction between growth hormone-releasing hormone (GHRH) and growth hormone secretagogue (GHS) signaling at the level of the anterior pituitary somatotroph.

CJC-1295 no DAC, also known as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic 29-amino acid analog of the first 29 residues of native GHRH(1-44). Four amino acid substitutions have been introduced at positions 2, 8, 15, and 27 (D-Ala2, Asn8, Ala15, and Nle27) to confer resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and other serum proteases, while preserving full agonist activity at the GHRH receptor. The “no DAC” designation distinguishes this form from CJC-1295 with Drug Affinity Complex, which incorporates a maleimido-propionic acid linker that enables covalent binding to serum albumin, extending its half-life to approximately 8 days. The no DAC form intentionally forgoes this albumin-binding modification, retaining a shorter half-life of approximately 30 minutes that produces discrete, physiologically relevant GH pulses.

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin mimetic with a molecular weight of 711.85 g/mol that activates the growth hormone secretagogue receptor type 1a (GHS-R1a) on anterior pituitary somatotrophs. Developed by Novo Nordisk, Ipamorelin is distinguished from earlier GHS peptides (such as GHRP-6 and GHRP-2) by its remarkably high selectivity for GH release, with minimal or no stimulation of cortisol, ACTH, or prolactin secretion at GH-effective doses. This selectivity makes it the preferred GHS component for combination protocols where clean, GH-specific stimulation is desired.

The scientific rationale for combining a GHRH analog with a GHS is grounded in decades of research demonstrating that these two peptide classes activate mechanistically distinct intracellular signaling pathways that converge on somatotroph calcium signaling and GH granule exocytosis, producing true pharmacological synergy rather than simple additivity.

Mechanism of Action

The synergistic GH release achieved by the CJC-1295 no DAC / Ipamorelin combination can be understood through a detailed examination of the complementary intracellular signaling mechanisms engaged by each receptor system, and how their convergence on calcium signaling produces amplified hormonal output.

GHRH Receptor Pathway (CJC-1295 no DAC)

CJC-1295 no DAC binds to the GHRH receptor (GHRH-R), a class B (secretin family) G protein-coupled receptor expressed predominantly on anterior pituitary somatotrophs. The GHRH-R couples primarily to the Gs alpha subunit of heterotrimeric G proteins, and its activation initiates a well-characterized cAMP-dependent signaling cascade.

Upon ligand binding, GHRH-R activates adenylyl cyclase, catalyzing the conversion of ATP to cyclic adenosine monophosphate (cAMP). The resulting elevation in intracellular cAMP activates protein kinase A (PKA), which serves as the central effector kinase of the GHRH signaling pathway. PKA phosphorylates multiple downstream targets including L-type voltage-gated calcium channels (specifically Cav1.3 channels) in the somatotroph plasma membrane, increasing their open probability and driving calcium influx from the extracellular space. This calcium influx is the primary trigger for GH granule exocytosis through the GHRH pathway.

Beyond the acute secretory response, PKA activation also engages longer-term transcriptional programs. PKA phosphorylates and activates the transcription factor CREB (cAMP response element-binding protein), which binds to CRE elements in the GH gene promoter and drives GH mRNA transcription. This dual action means that GHRH receptor stimulation both releases pre-formed GH stores and replenishes them through new GH synthesis. Additionally, the cAMP/PKA/CREB pathway promotes somatotroph proliferation through Pit-1-dependent transcription, contributing to pituitary reserve maintenance.

The amino acid substitutions in CJC-1295 no DAC are designed specifically to enhance metabolic stability without altering receptor pharmacology. The D-Ala2 substitution prevents cleavage by DPP-IV, which rapidly inactivates native GHRH by removing the N-terminal Tyr-Ala dipeptide. The Asn8, Ala15, and Nle27 substitutions provide additional resistance to other serum proteases, collectively extending the effective half-life from the 7-10 minutes of native GHRH(1-44) to approximately 30 minutes.

GHS-R1a Receptor Pathway (Ipamorelin)

Ipamorelin binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a seven-transmembrane G protein-coupled receptor that also serves as the endogenous receptor for the gastric hormone ghrelin. GHS-R1a is expressed on pituitary somatotrophs, hypothalamic arcuate nucleus neurons, and various peripheral tissues. At the pituitary level, GHS-R1a couples primarily to the Gq/11 family of G proteins, initiating a phospholipase C (PLC)-dependent signaling cascade that is mechanistically distinct from the GHRH receptor’s cAMP-dependent pathway.

GHS-R1a-mediated Gq/11 activation stimulates PLC-beta, which hydrolyzes membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to IP3 receptors on the endoplasmic reticulum membrane, triggering the release of calcium from intracellular stores. This IP3-mediated calcium release from internal stores represents a fundamentally different calcium source than the extracellular calcium influx driven by GHRH-R signaling. Simultaneously, DAG activates protein kinase C (PKC), which modulates ion channel activity and further enhances calcium signaling.

Additionally, GHS-R1a signaling involves cross-talk with the hypothalamic GHRH pathway. Ipamorelin, acting at hypothalamic GHS-R1a receptors, stimulates GHRH neurons in the arcuate nucleus, amplifying endogenous GHRH release. This hypothalamic component adds a third tier of GH stimulation beyond the direct pituitary effects.

Ipamorelin’s selectivity is noteworthy. Unlike GHRP-6, which activates adrenal GHS-R and stimulates ACTH and cortisol release, and unlike GHRP-2, which has partial cross-reactivity with other receptors, Ipamorelin demonstrates no significant stimulation of ACTH, cortisol, or prolactin at doses that produce maximal GH release. This selectivity has been attributed to its unique binding orientation within the GHS-R1a binding pocket, which produces conformational changes that preferentially couple to GH-releasing signaling pathways.

Molecular Basis of Synergy

The synergistic effect of co-administering a GHRH analog with a GHS is one of the most reproducible and well-characterized phenomena in neuroendocrine pharmacology. The amplified GH response arises because the two receptor pathways converge on intracellular calcium through independent and complementary mechanisms.

GHRH-R signaling primarily drives calcium influx through voltage-gated calcium channels in the plasma membrane (extracellular calcium source), while GHS-R1a signaling primarily mobilizes calcium from intracellular endoplasmic reticulum stores through IP3-mediated release (intracellular calcium source). The simultaneous engagement of both calcium sources produces a combined calcium signal that far exceeds what either pathway generates independently. This elevated calcium concentration maximally activates the calcium-dependent exocytotic machinery (SNARE complexes, synaptotagmin) responsible for GH granule release.

Landmark studies by Veldhuis, Iranmanesh, and Bowers quantified this synergy by comparing GH responses to GHRH alone, GHS alone, and the combination. Their data demonstrated that co-administration produces GH release amplitudes 2-3 times greater than the arithmetic sum of individual responses, meeting the formal pharmacological definition of synergy (supra-additive response). This synergistic amplification was observed across multiple study populations, including young adults, elderly subjects, and individuals with partial GH deficiency.

Additional mechanisms contributing to the synergy include PKC-mediated sensitization of voltage-gated calcium channels (making them more responsive to the cAMP/PKA signal from GHRH-R), and cAMP-dependent priming of IP3 receptor sensitivity (enhancing the calcium release triggered by GHS-R1a signaling). These cross-pathway interactions create a positive feedback loop that amplifies the combined response beyond what either pathway’s independent calcium contribution would predict.

Pulsatile Release Profile and Somatostatin Interaction

Because CJC-1295 no DAC (without the Drug Affinity Complex) has a relatively short half-life of approximately 30 minutes, the combination blend produces discrete GH pulses rather than sustained elevation. This pulsatile release pattern is physiologically advantageous because it mirrors the natural ultradian rhythm of GH secretion, which occurs in 6-12 pulses per day with the largest pulse occurring during early slow-wave sleep.

Pulsatile GH delivery preserves GH receptor sensitivity through normal receptor cycling and internalization, whereas sustained GH elevation leads to receptor downregulation and tachyphylaxis. The pulsatile pattern also maintains the normal regulatory interplay between GH, IGF-1, and somatostatin. Between pulses, somatostatin tone recovers, allowing GH stores to be replenished through ongoing GHRH-driven GH gene transcription. The preserved somatostatin regulation also prevents the glucose intolerance and insulin resistance that can develop with sustained GH elevation.

Pharmacokinetics

CJC-1295 no DAC Pharmacokinetics

CJC-1295 no DAC (Modified GRF 1-29) demonstrates pharmacokinetic properties specifically engineered to balance metabolic stability with physiological pulsatility. Following subcutaneous administration, peak plasma concentrations are achieved within 15-30 minutes. The terminal elimination half-life is approximately 30 minutes, approximately 3-4 times longer than native GHRH(1-44), which has a half-life of only 7-10 minutes due to rapid DPP-IV cleavage.

The primary route of degradation is through endopeptidase activity, though the four amino acid substitutions substantially reduce susceptibility to the most common degradation pathways. The D-Ala2 substitution is the most pharmacokinetically significant modification, as DPP-IV cleavage of the N-terminal dipeptide is the primary inactivation pathway for native GHRH and accounts for more than 95% of first-pass degradation.

The relatively short half-life of CJC-1295 no DAC means that its pharmacodynamic effects (GH pulse generation) are confined to a discrete window of approximately 1-2 hours post-administration, after which somatotroph stimulation ceases and normal somatostatin-mediated quiescence resumes. This discrete pharmacodynamic window is the key distinction from CJC-1295 with DAC, which produces sustained, non-pulsatile GH elevation for 7-10 days.

Ipamorelin Pharmacokinetics

Ipamorelin demonstrates rapid absorption following subcutaneous administration, with peak plasma concentrations (Tmax) achieved within 20-30 minutes. The elimination half-life is approximately 2 hours, longer than earlier GHS peptides such as GHRP-6 (approximately 60 minutes), providing an extended window of GHS-R1a activation. Ipamorelin is eliminated primarily through renal clearance and peptidase degradation.

The pharmacokinetic profiles of the two components are complementary. CJC-1295 no DAC reaches peak activity quickly and provides a strong initial GHRH-R stimulus, while Ipamorelin’s somewhat longer half-life extends the GHS-R1a co-stimulation, maintaining the synergistic calcium signal throughout the GH secretory pulse.

Combined Pharmacodynamic Profile

When the two peptides are administered together, the GH secretory response begins within 10-15 minutes, peaks at approximately 30-45 minutes, and returns to baseline within 2-3 hours. This pharmacodynamic profile reflects the integration of both receptor pathways and the resulting amplified calcium signaling in somatotrophs.

The peak GH concentrations achieved with the combination are substantially higher than those achieved with either peptide alone. In research settings, the combination has been shown to produce GH peaks of 30-100 ng/mL or higher, depending on dose, age, body composition, and baseline somatotroph reserve. For comparison, monotherapy with either CJC-1295 no DAC or Ipamorelin alone typically produces peak GH levels of 5-20 ng/mL.

The pharmacodynamic synergy is also evident in the area under the curve (AUC) for GH secretion, which is typically 2-3 fold greater than the sum of individual component AUCs. This supra-additive AUC reflects both the higher peak GH concentration and the broader GH pulse duration achieved with combined stimulation.

Research Applications

Growth Hormone Axis Research

The CJC-1295 no DAC / Ipamorelin combination has become one of the most widely used research tools for investigating GH physiology, somatotroph biology, and the neuroendocrine regulation of the GH-IGF-1 axis:

• Synergy quantification: Used to study the molecular mechanisms underlying GHRH-GHS synergy in somatotroph calcium signaling, including the relative contributions of extracellular calcium influx versus intracellular calcium release
• Pituitary reserve testing: The combination provides the most robust peptide-based stimulus for assessing maximal pituitary GH secretory capacity, serving as a functional test of somatotroph number and responsiveness
• Age-related GH decline: Research into whether the combination can overcome the somatopause, the progressive decline in GH secretion associated with aging that is characterized by reduced GH pulse amplitude, reduced somatotroph GHRH-R expression, and increased somatostatin tone
• Feedback regulation: Studies on how IGF-1 negative feedback and somatostatin tone modulate the response to combined GHRH/GHS stimulation
• Dose-response characterization: Research establishing the optimal molar ratio and absolute doses of the two components for maximal synergistic effect
• Receptor cross-talk: Investigation of how GHRH-R and GHS-R1a interact at the membrane level, including evidence for receptor heterodimerization and allosteric modulation

Body Composition and Muscle Growth

Through robust stimulation of the GH-IGF-1 axis, the combination blend has been extensively studied for its effects on body composition parameters:

• Lean mass accretion: Enhanced GH pulsatility promotes nitrogen retention, increased muscle protein synthesis through the GH-IGF-1-mTOR axis, and satellite cell activation in skeletal muscle
• Fat metabolism: GH-mediated activation of hormone-sensitive lipase drives lipolysis in adipose tissue, while reduced lipogenesis and enhanced fatty acid oxidation contribute to shifts in body composition toward increased lean mass and reduced fat mass
• Visceral adiposity: Research examining whether the combination’s amplified GH release can preferentially reduce visceral adipose tissue, the metabolically active depot most responsive to GH-mediated lipolysis
• Recovery from catabolic states: Research in post-injury, post-surgical, and immobilization models evaluating the combination’s ability to preserve lean tissue during catabolic conditions through GH-mediated anti-catabolic effects
• Comparison studies: Head-to-head evaluations of the combination’s effects against monotherapy with either peptide alone, sermorelin, and other GHRH-GHS combinations

Recovery and Repair Research

The amplified GH release from the combination has been investigated in multiple tissue repair and recovery research contexts:

• Collagen synthesis: GH and IGF-1 stimulate fibroblast proliferation, type I and type III collagen production, and extracellular matrix remodeling, relevant to connective tissue repair following injury
• Bone remodeling: Research on the combination’s effects on osteoblast activity, bone formation markers (osteocalcin, P1NP), and skeletal remodeling through the GH-IGF-1 axis
• Tendon and ligament repair: Investigation of GH-mediated collagen synthesis in tendons and ligaments, where IGF-1 receptor signaling drives tenocyte proliferation and matrix production
• Sleep architecture: GH secretion is closely linked to deep slow-wave sleep. Research has explored whether evening administration of the combination enhances slow-wave sleep quality and duration, creating a positive feedback loop with endogenous GH secretion
• Post-exercise recovery: Studies examining whether the combination’s GH-amplifying effects accelerate recovery markers (inflammatory cytokines, creatine kinase clearance, glycogen replenishment) following strenuous exercise protocols

Aging and Somatopause Research

The age-related decline in GH secretion (somatopause) is associated with progressive changes in body composition, bone density, cognitive function, and cardiovascular risk. The CJC-1295 no DAC / Ipamorelin combination has been investigated as a research tool for understanding and potentially counteracting these changes:

• Somatotroph responsiveness: Research demonstrating that aged somatotrophs retain the capacity to respond to combined GHRH/GHS stimulation, suggesting that the somatopause reflects primarily hypothalamic dysregulation rather than intrinsic somatotroph failure
• GH pulse restoration: Studies showing that the combination can restore GH pulse amplitudes in aged subjects to levels approaching those seen in younger individuals
• IGF-1 normalization: Research on whether the combination’s amplified GH release translates to meaningful increases in circulating IGF-1 levels in aged populations

Safety Profile in Research

Individual Component Safety Data

Both components of the blend have been evaluated in preclinical and clinical research settings with well-characterized safety profiles.

CJC-1295 no DAC: Modified GRF(1-29) has been administered in multiple clinical studies without serious adverse events. The most commonly reported effects include transient injection site reactions (erythema, mild pain), facial flushing lasting 5-15 minutes post-injection (attributed to vasodilation from the peptide’s structural similarity to vasoactive intestinal peptide), and occasional mild headache. No significant effects on cortisol, ACTH, prolactin, TSH, or LH/FSH have been reported at GH-stimulating doses, confirming the specificity of the GHRH receptor pathway for GH release.

Ipamorelin: Clinical studies of Ipamorelin have demonstrated an exceptionally clean side effect profile compared to other GHS compounds. At GH-maximizing doses, Ipamorelin does not significantly elevate cortisol, ACTH, or prolactin, distinguishing it from GHRP-6 (which stimulates ACTH and cortisol) and GHRP-2 (which elevates cortisol and prolactin). The most common reported effects are transient injection site reactions and mild, short-lived increases in appetite consistent with GHS-R1a activation in the hypothalamic feeding circuits.

Combination Safety Considerations

When used in combination, the safety profile reflects the individual component profiles without evidence of synergistic adverse effects. The primary considerations include:

• Transient flushing: May be more pronounced with the combination due to the vasodilatory properties of the GHRH analog component
• GH-related effects: With sustained use, the amplified GH secretion may produce effects associated with elevated GH including water retention, joint stiffness, and transient paresthesias, particularly at higher doses
• Blood glucose: GH is a counter-regulatory hormone that antagonizes insulin action. Monitoring of glucose metabolism is standard practice in GH axis research protocols
• Tachyphylaxis: Continuous, high-frequency dosing may lead to reduced responsiveness through somatostatin upregulation and GH store depletion; cycling protocols are commonly employed in research settings

Dosing in Research Literature

The following table summarizes representative dosing approaches reported in the literature for the individual components and their combination:

Molecular Properties

Storage and Handling for Research

The lyophilized blend should be stored at -20°C or below for long-term stability. Both peptide components maintain their structural integrity and biological activity under these conditions for extended periods. The blend is stable at room temperature during brief handling and shipping, but prolonged exposure to temperatures above 4°C should be avoided.

After reconstitution with bacteriostatic water, the solution should be refrigerated at 2-8°C and used within 30 days. The two peptides are chemically compatible in aqueous solution at standard research concentrations and do not form aggregates, precipitates, or undergo cross-reactions that would compromise their individual receptor activities. Both components are stable in the pH range of 5.0-7.5, which encompasses typical bacteriostatic water formulations.

Current Research Landscape

The CJC-1295 no DAC / Ipamorelin combination continues to be one of the most widely studied peptide combinations in growth hormone research, with active investigation in multiple research domains:

1. Optimized dosing ratios: Ongoing research into the ideal molar ratio of GHRH analog to GHS for maximal synergistic effect, including studies comparing fixed-ratio blends with independently titrated components
2. Aging and somatopause: Studies evaluating whether the combination can restore youthful GH secretory patterns in aged subjects and whether this restoration translates to meaningful improvements in age-related endpoints including body composition, bone density, and cognitive function
3. Metabolic research: Investigation of the combination’s effects on glucose metabolism, insulin sensitivity, lipid profiles, and hepatic fat content, with particular interest in whether pulsatile GH stimulation has different metabolic consequences than sustained GH elevation
4. Comparison with other GHRH-GHS combinations: Research comparing CJC-1295 no DAC / Ipamorelin with sermorelin / GHRP-2, sermorelin / GHRP-6, tesamorelin / Ipamorelin, and other combination protocols to determine relative efficacy and safety profiles
5. Chronobiology: Studies on optimal timing of administration relative to sleep, meals, exercise, and circadian rhythm for maximal physiological GH pulsatility and downstream IGF-1 generation
6. Long-term effects: Extended research protocols examining the combination’s effects on sustained body composition changes, bone mineral density, and markers of biological aging over months to years of pulsatile GH stimulation

References

The studies referenced throughout this monograph represent foundational and current literature on GHRH-GHS synergy and the individual components of this blend. For comprehensive research, search PubMed and Google Scholar using terms such as “CJC-1295,” “Modified GRF 1-29,” “ipamorelin,” “GHRH GHS synergy,” “growth hormone secretagogue combination,” or “somatotroph calcium signaling” for the latest publications.